- Technology Management
- For Industry - Technology Available for Licensing
- Contact Technology Management
- old pages
- title page
- A Modern Approach to Wing Warp for Aircraft Control
- Treatment Of Liver Fibrosis Following Hepatic Injury By Selective Killing Of Activated Liver Stellate Cells
- Compositions and Methods for Treating and Diagnosing Hepatoma
- Vaccine Compositions and Methods That Increase Safety of Anti-Viral Vaccination Without Loss of Efficacy
- Automatic Pressure-Locking Valve Prevents CSF Loss and Herniation During Lumbar Puncture When Intracranial Pressure Is Elevated.
- Immortal Differentiated Type II Lung Epithelial Cell Line (T7)
- Human A Rapid, Reliable Bedside Diagnostic Method For Accurately Determining Feeding Tube Placement In Respiratory Tract, Stomach, Or Small Bowel Of Patients Prior to Enteral Nutrient Administration.
- Human Natural Killer Cell Line - NK 3.3:
- Factor IXa Protease Helix-330 (Region 1)
- In Vitro Method for Concerted Integration of Donor DNA Molecules Into Target DNA Using Retroviral Integrase and a Procedure for Evaluation of Donor DNA Integration.
- SRCAP: A Novel Transcription Protein Having Therapeutic Target and Diagnostic Target Product Development Potential.
- C-Terminal Binding Protein Interacting Protein (CtIP):
- Novel Anti-Coagulation Therapeutics: Agents That Effectively Inhibit Binding of Factor VIIIa (Region 3) With Factor IXa (Region 2) Without Activating Factor X.
- Genetically Modified Activated Protein C with Reduced Anticoagulant Properties
- C22: A Conditionally Immortalized Mouse Clara Cell Line
Immortal Differentiated Type II Lung Epithelial Cell Line (T7)
Inventor: Daphne E. deMello, M.D.
Lung type II epithelial cells are present in the alveolar lining and produce the surface tension lowering lipoprotein complex, surfactant. When surfactant is absent or deficient, as in premature infants or certain pathological states in adults, respiratory distress ensues. The lack of a suitable in vitro cell model has hampered biologic and metabolic studies of lung surfactant synthesis and secretion.
The T7 cell line, the first non-tumor derived immortalized fully differentiated lung type II cell line, was produced from lungs of transgenic H-2Kb-tsA58 mice. This cell line synthesizes the surfactant proteins SP-A, SP-B and SP-C plus phosphatidylcholine, the major components of pulmonary surfactant.
T7 cells demonstrate differentiated secretion of surfactant proteins and phospholipids at both 33¢ªC and 39¢ªC. At 39¢ªC, however, these cells exhibit progressive loss of cell proliferation and eventual cell death, which does not occur at 33¢ªC. The T7 cells have Type II cell specific biochemical and morphological features, can be maintained indefinitely in cell culture, and can be clonally expanded with ease.
The immortal differentiated lung type II lung epithelial cell line (T7) will be useful to pulmonary researchers and clinicians for: (i) studying the multiple aspects of Type II lung cell biology and metabolism, (ii) screening new drugs for their ability to affect the synthesis and secretion of pulmonary surfactant proteins and lipids, and, (iii) production of Type II lung cell lipids and surfactant proteins intended for therapeutic uses.
Category: Immortal Type II lung cell line
Keywords: immortal, Type II, pulmonary, ARDS, pulmonary surfactant, assay, drug screening
Reference Number: SLU-1015